We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended December 2023, Johnson & Johnson (JNJ - Free Report) reported revenue of $21.4 billion, down 9.8% over the same period last year. EPS came in at $2.29, compared to $2.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $21.11 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.27.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Sales Growth (Operational growth): 7.2% compared to the 7.1% average estimate based on two analysts.
Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $206 million versus the five-analyst average estimate of $211.98 million.
Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $159 million versus the five-analyst average estimate of $172.04 million.
Sales- MedTech- Orthopaedics- Hips- US: $266 million versus the four-analyst average estimate of $262.75 million. The reported number represents a year-over-year change of +6.4%.
Sales- MedTech- Orthopaedics- Hips- International: $132 million versus $137.28 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change.
Sales- Innovative Medicine- WW: $13.72 billion versus the six-analyst average estimate of $13.41 billion. The reported number represents a year-over-year change of +4.3%.
Sales- MedTech- Total: $7.67 billion compared to the $7.48 billion average estimate based on six analysts. The reported number represents a change of +13.2% year over year.
Sales- Innovative Medicine- Infectious Diseases- Other Infectious Diseases- WW: $62 million versus $64.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.
Sales- Innovative Medicine- Infectious Diseases- Edurant / rilpivirine- WW: $307 million versus the five-analyst average estimate of $340.22 million. The reported number represents a year-over-year change of +5.9%.
Sales- Innovative Medicine- Neuroscience- INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA- WW: $1.01 billion compared to the $1 billion average estimate based on five analysts. The reported number represents a change of +0.3% year over year.
Sales- MedTech- Vision- WW: $1.21 billion versus the five-analyst average estimate of $1.21 billion. The reported number represents a year-over-year change of +5.5%.
Sales- Innovative Medicine- Oncology- ZYTIGA / abiraterone acetate- WW: $201 million compared to the $144.99 million average estimate based on five analysts. The reported number represents a change of -25.6% year over year.
Shares of Johnson & Johnson have returned +4.5% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended December 2023, Johnson & Johnson (JNJ - Free Report) reported revenue of $21.4 billion, down 9.8% over the same period last year. EPS came in at $2.29, compared to $2.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $21.11 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.27.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Sales Growth (Operational growth): 7.2% compared to the 7.1% average estimate based on two analysts.
- Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $206 million versus the five-analyst average estimate of $211.98 million.
- Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $159 million versus the five-analyst average estimate of $172.04 million.
- Sales- MedTech- Orthopaedics- Hips- US: $266 million versus the four-analyst average estimate of $262.75 million. The reported number represents a year-over-year change of +6.4%.
- Sales- MedTech- Orthopaedics- Hips- International: $132 million versus $137.28 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change.
- Sales- Innovative Medicine- WW: $13.72 billion versus the six-analyst average estimate of $13.41 billion. The reported number represents a year-over-year change of +4.3%.
- Sales- MedTech- Total: $7.67 billion compared to the $7.48 billion average estimate based on six analysts. The reported number represents a change of +13.2% year over year.
- Sales- Innovative Medicine- Infectious Diseases- Other Infectious Diseases- WW: $62 million versus $64.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.
- Sales- Innovative Medicine- Infectious Diseases- Edurant / rilpivirine- WW: $307 million versus the five-analyst average estimate of $340.22 million. The reported number represents a year-over-year change of +5.9%.
- Sales- Innovative Medicine- Neuroscience- INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA- WW: $1.01 billion compared to the $1 billion average estimate based on five analysts. The reported number represents a change of +0.3% year over year.
- Sales- MedTech- Vision- WW: $1.21 billion versus the five-analyst average estimate of $1.21 billion. The reported number represents a year-over-year change of +5.5%.
- Sales- Innovative Medicine- Oncology- ZYTIGA / abiraterone acetate- WW: $201 million compared to the $144.99 million average estimate based on five analysts. The reported number represents a change of -25.6% year over year.
View all Key Company Metrics for Johnson & Johnson here>>>Shares of Johnson & Johnson have returned +4.5% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.